Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.
A few weeks ago Belgium's Galapagos touted some early-stage data on GLPG1205, a new drug for inflammatory bowel diseases which it discovered under a $1 billion-plus partnership deal inked with J&J back in 2007. But today J&J bowed out of the pact for the entire GPR84 program, an effort that includes GLPG1205 and its backup compound GLPG2196.
J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested the drug in a head-to-head trial.
The National Institute for Health and Care Excellence decided to reverse course on a new use for Johnson & Johnson's anti-inflammatory drug Stelara, thanks to a new discount offer.
The FDA has cleared the VEPTR and VEPTR II Vertical Expandable Prosthetic Titanium Rib Devices to treat children with thoracic insufficiency syndrome, a rare congenital condition that results in severe deformities of the chest, spine or ribs that impair breathing and lung growth.
Covidien lost a battle in its years-long patent war with Johnson & Johnson's Ethicon unit, as a top U.S. patent appeals court tossed out a $176 million award for the company and ruled that its claims regarding J&J/Ethicon's Harmonic line ultrasonic surgical tools were invalid.
Genmab reports that its partners at J&J are starting a Phase II study of daratumumab in non-Hodgkin's lymphoma.
Bayer and Johnson & Johnson are fighting a consolidation of lawsuits over their top-selling anticoagulant Xarelto, months after patients filed suit in the U.S. accusing the companies of downplaying the drug's risks.
After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.
These days, sometimes it's not enough to prove your drug is more effective than the standard of care. As rising drug costs continue to trigger concerns and pushback among payers, providers and patients, it's not a bad idea to prove your drug can beat the old guard on cost--or at the very least, match it. And that's just what Johnson & Johnson's Janssen unit says it's done with Xarelto.